

**THE FOLLOWING DRUGS WILL BE REVIEWED AT THE  
DRUG UTILIZATION REVIEW BOARD MEETING**

**March 17, 2011**

**Georgia Department of Community Health**

**[This list may change at any time. Please check back frequently for updates.](#)**

**New Drugs for Review**

<b>Therapeutic Class</b>	<b>Drug Name</b>	<b>Current PDL Status</b>
<b>Gastrointestinal – Digestive Enzyme</b>		
	Pancreaze	P
<b>Oral Contraceptive</b>		
	Natazia	NP/PA
<b>Sedative Hypnotic</b>		
	Silenor	NP/PA

**Supplemental Rebate Drugs or Classes for Review**

Drugs or classes highlighted in **RED** below have been added since the last Manufacturers' Forum. As a result, manufacturers of these drugs or classes in **RED** below may present clinical information to NorthStar HealthCare Consulting on Wednesday, March 9, 2011 or may submit any electronic clinical information on these drugs or classes in **RED** below by March 9, 2011. Please submit meeting requests and/or clinical information to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com).

**Besivance, Cephadyn, Fareston, LoSeasonique, Norvir, NuZole, Pylera, Seasonique, Singulair, Vigamox, Wilate, Zmax, Zylet, Zymar, Zymaxid**

**Direct Renin Inhibitors and Combinations**

**Adrenergic Combinations**

**Alzheimer Cholinomimetics**

**Androgens/Anabolics**

**Angiotensin II Receptor Blockers and Combinations**

**Anticholinergics**

**Anticoagulants**

**Anticonvulsants**

**Antidepressants – Selective Serotonin Reuptake Inhibitors**

**Antidepressants – Serotonin Norepinephrine Reuptake Inhibitors**

<b>Antiemetics</b>
<b>Antihistamines – Nasal</b>
<b>Antihistamines – Non-Sedating</b>
<b>Antihyperkinesis Agents</b>
<b>Antispasmodics</b>
<b>Atypical Antipsychotics</b>
<b>Beta Adrenergics – Short-Acting Inhalers</b>
<b>Beta Blockers</b>
<b>Benign Prostatic Hyperplasia Agents</b>
<b>Cardiac – Other</b>
<b>Calcium Channel Blocker/Statin Combinations</b>
<b>Cephalosporins</b>
<b>Cholesterol Bile Acid Sequestrants</b>
<b>Cough and Cold Products</b>
<b>Diabetic – Dipeptidyl Peptidase IV Inhibitors</b>
<b>Diabetic – Meglitinides</b>
<b>Diabetic – Non-Insulin Injectables</b>
<b>Drugs Affecting the Ear</b>
<b>Endothelin Receptor Agonists</b>
<b>Erythropoiesis Stimulating Agents</b>
<b>Fluoroquinolones</b>
<b>Gastrointestinal – Digestive Enzymes</b>

<b>Gastrointestinal – Inflammatory Bowel Agents</b>
<b>Gastrointestinal – Proton Pump Inhibitors</b>
<b>Glucocorticoids</b>
<b>Growth Hormones</b>
<b>Hepatitis C Agents</b>
<b>Hyperparathyroid – Vitamin D Analogs and Calcimimetics</b>
<b>Insulins</b>
<b>Insulin Pens</b>
<b>Lipid - Niacins</b>
<b>Lipid - Others</b>
<b>Migraine - Selective Serotonin Agonists</b>
<b>Miscellaneous</b>
<b>Multiple Sclerosis Agents</b>
<b>Narcotics – Miscellaneous</b>
<b>Narcotics – Long-Acting</b>
<b>Nasal Steroids</b>
<b>Nonsteroidal Antiinflammatory Cyclooxygenase-2 Selective Agents</b>
<b>Nonsteroidal Antiinflammatory Agents</b>
<b>Ophthalmic Antihistamines</b>
<b>Ophthalmic Beta Blockers</b>
<b>Ophthalmic Nonsteroidal Antiinflammatory Agents</b>
<b>Ophthalmic Prostaglandins</b>
<b>Ophthalmic Selective Alpha Adrenergic Agonists</b>

<b>Opioid Partial Agonists</b>
<b>Phosphate Binders</b>
<b>Platelet Aggregate Inhibitor Combinations</b>
<b>Statins – High Potency</b>
<b>Statins – Low Potency</b>
<b>Steroid Inhalants</b>
<b>Topical – Antiacne Preparations</b>
<b>Topical – Antibiotics</b>
<b>Topical – Antipsoriatics</b>
<b>Topical – Corticosteroids</b>
<b>Topical – Immunomodulators</b>
<b>Topical – Local Anesthetics</b>
<b>Triglyceride Lowering Agents</b>
<b>Tumor Necrosis Factor Blockers</b>
<b>Vitamins</b>

**PDL** = Preferred Drug List

**P** = Preferred

**NP** = Non-Preferred

**PA** = Prior Authorization